HOOKIPA Pharma reported Q2 2024 revenue of $1.3 million, down from $2.7 million in Q2 2023, with a net loss of $19.1 million. The revenue decline primarily resulted from lower recognition of upfront and milestone payments following the Roche collaboration termination. Research and development expenses remained stable at $19.7 million, while general and administrative expenses decreased to $3.9 million from $4.4 million YoY.The company announced a strategic refocus in January 2024, prioritizing its eseba-vec program for HPV16+ head and neck cancers and Gilead-partnered infectious disease programs. This restructuring included a 30% workforce reduction and discontinuation of the GMP manufacturing facility project, resulting in $1.3 million in restructuring charges for H1 2024. The restructuring was completed by Q2 end.As of June 30, 2024, HOOKIPA had cash and equivalents of $77.4 million, down from $117.5 million at 2023 year-end. Management expressed substantial doubt about the company's ability to continue as a going concern, citing the need for additional funding to support planned operations beyond the next 12 months. The company is pursuing additional capital through partnerships, equity or debt financing options.

HOOKIPA Pharma reported Q2 2024 revenue of $1.3 million, down from $2.7 million in Q2 2023, with a net loss of $19.1 million. The revenue decline primarily resulted from lower recognition of upfront and milestone payments following the Roche collaboration termination. Research and development expenses remained stable at $19.7 million, while general and administrative expenses decreased to $3.9 million from $4.4 million YoY.The company announced a strategic refocus in January 2024, prioritizing its eseba-vec program for HPV16+ head and neck cancers and Gilead-partnered infectious disease programs. This restructuring included a 30% workforce reduction and discontinuation of the GMP manufacturing facility project, resulting in $1.3 million in restructuring charges for H1 2024. The restructuring was completed by Q2 end.As of June 30, 2024, HOOKIPA had cash and equivalents of $77.4 million, down from $117.5 million at 2023 year-end. Management expressed substantial doubt about the company's ability to continue as a going concern, citing the need for additional funding to support planned operations beyond the next 12 months. The company is pursuing additional capital through partnerships, equity or debt financing options.